0000358654
Donate

Reimbursement status:
Full reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Venetoclax in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Venclyxto monotherapy is indicated for the treatment of CLL: • in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or • in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XX
L01XX Other antineoplastic agents
EMA approval status :
Approved
EMA approval date :
2016-12-05
EMA conditional? :
Yes
EMA orphan? :
Yes
EMA biological? :
No